Cohance Lifesciences Q2 FY27 Financial and Operational Performance Overview
Cohance Lifesciences Ltd 路 Investor Presentation 路 07 Nov 2026, 10:25 pm
Cohance Lifesciences Q2 FY27 Financial and Operational Performance Overview Cohance Lifesciences reported Q2 FY27 revenue of INR 4,767 Mn, down 14.2% YoY but recovering 12.9% QoQ. Adjusted EBITDA stood at INR 458 Mn with margins improving sequentially to 9.6% from 2.2% in Q1. Adjusted PAT turned positive at INR 75 Mn. H1 FY27 revenue fell 18.6% YoY to INR 8,989 Mn. API+ grew 5% YoY in Q2, while Sapala surged 33.6% YoY. Management expects stronger H2 performance driven by Pharma CDMO reload deliveries, API+ resilience, and higher capacity utilisation. Net cash stood at INR 666 Mn as of 30th Sep'26.
Original exchange filing (PDF)
More announcements from Cohance Lifesciences Ltd
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings .... 路 12 Nov 2026
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 12 Nov 2026
- Investors Meet 路 11 Nov 2026
- Transcript of Con call 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings Pvt Ltd & Others 路 11 Nov 2026
- Update on USFDA inspection at Pashamylaram Manufacturing facility. 路 07 Nov 2026
- Audio link for the conference call 路 07 Nov 2026
